tiprankstipranks
Trending News
More News >
MetaVia (MTVA)
NASDAQ:MTVA
US Market
Advertisement

MetaVia (MTVA) Drug Pipeline

Compare
383 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Da-1726
Obesity
Phase I
Recruiting
First in Human Study in Subjects With Obesity, But Otherwise Healthy
Jan 09, 2024
Sitagliptin, Da-1241
Non-Alcoholic Steatohepatitis
Phase II
Completed
Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
Sep 05, 2023
Niclosamide
Healthy
Phase I
Completed
A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers
Dec 08, 2020
Niclosamide
Covid-19
Phase II/III
Completed
Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
Oct 20, 2020

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does MetaVia (MTVA) have in its pipeline
      MTVA is currently developing the following drugs: Da-1726, Sitagliptin, Da-1241, Niclosamide. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis